98224-27-2

Basic information

• Product Name: 1-BENZO[1,3]DIOXOL-4-YL-PIPERAZINE
• Synonyms: 1-BENZO[1,3]DIOXOL-4-YL-PIPERAZINE;1-(Benzo[d][1,3]dioxol-4-yl)piperazine
• CAS NO: 98224-27-2
• Molecular Formula: C₁₁H₁₄N₂O₂
• Molecular Weight: 206.24106
• Mol File: 98224-27-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 367.304°C at 760 mmHg
• Flash Point: 175.939°C
• Appearance: /
• Density: 1.221g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.577
• CAS DataBase Reference: 1-BENZO[1,3]DIOXOL-4-YL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZO[1,3]DIOXOL-4-YL-PIPERAZINE(98224-27-2)
• EPA Substance Registry System: 1-BENZO[1,3]DIOXOL-4-YL-PIPERAZINE(98224-27-2)

Safety Data

• Hazardous Substances Data: 98224-27-2(Hazardous Substances Data)

Usage

General Description

1-Benzo[1,3]dioxol-4-yl-piperazine is a chemical compound with potential pharmaceutical applications. It is a piperazine derivative, which is a class of compounds used in the development of pharmaceutical drugs and other chemical products. The presence of the benzo[1,3]dioxol moiety in the structure of this compound suggests potential bioactive properties. Piperazine derivatives have been studied for their potential use in treating a variety of medical conditions, including psychiatric disorders and neurological diseases. This particular compound may hold promise for potential pharmacological activity, making it a subject of interest in pharmaceutical research and development.

InChI:InChI=1/C11H14N2O2/c1-2-9(13-6-4-12-5-7-13)11-10(3-1)14-8-15-11/h1-3,12H,4-8H2

Upstream product

• 72744-45-7 4-nitro-(1,3-benzodioxolyl) 
• 6665-98-1 3-nitrobenzene-1,2-diol 
• 1668-84-4 benzo[d][1,3]dioxol-4-amine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Relevant articles and documents

Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT1A receptors

It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]-thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (Ki 1A receptors (Ki 35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h-j and 8j,1 antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.